Company Description
Olema Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapies for women’s cancers.
The company’s lead product candidate is palazestrant, an estrogen receptor (ER) antagonist and a selective ER degrader, which is in Phase 3 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive, human epidermal growth factor receptor 2-negative breast cancer; OPERA-01, the pivotal Phase 3 clinical trial of palazestrant as a monotherapy in second/third-line ER+/HER2- metastatic breast cancer; and palazestrant with CDK4/6 inhibitors palbociclib and ribociclib, a phosphatidylinositol 3 kinase alpha (PI3Ka) inhibitor alpelisib, and with an mTOR inhibitor everolimus that is in Phase 1/2 clinical trial for the treatment of recurrent, locally advanced, or metastatic estrogen receptor-positive human epidermal growth factor receptor 2-negative breast cancer.
It also develops OP-3136, an orally-available small molecule that potently and selectively inhibits KAT6 for patients with ER+/HER2- metastatic breast cancer and other cancers which is in Phase 1 clinical trial.
The company was formerly known as CombiThera, Inc. and changed its name to Olema Pharmaceuticals, Inc. in March 2009.
Olema Pharmaceuticals, Inc. was incorporated in 2006 and is headquartered in San Francisco, California.
| Country | United States |
| Founded | 2006 |
| IPO Date | Nov 19, 2020 |
| Industry | Biotechnology |
| Sector | Healthcare |
| Employees | 96 |
| CEO | Sean Bohen |
Contact Details
Address: 780 Brannan Street San Francisco, California 94103 United States | |
| Phone | 415 651 3316 |
| Website | olema.com |
Stock Details
| Ticker Symbol | OLMA |
| Exchange | NASDAQ |
| Stock Type | Common Stock |
| Fiscal Year | January - December |
| Reporting Currency | USD |
| IPO Price | $19.00 |
| CIK Code | 0001750284 |
| CUSIP Number | 68062P106 |
| ISIN Number | US68062P1066 |
| Employer ID | 30-0409740 |
| SIC Code | 2834 |
Key Executives
| Name | Position |
|---|---|
| Dr. Sean P. Bohen M.D., Ph.D. | President, Chief Executive Officer and Director |
| Shane William Charles Kovacs M.B.A. | Chief Operating and Financial Officer |
| Dr. Naseem Zojwalla M.D. | Chief Medical Officer |
| Shawnte M. Mitchell J.D. | Chief Legal Officer and Corporate Secretary |
| Courtney O'Konek | Vice President of Corporate Communications |
| Julie Dexter | Senior Vice President and Head of People |
| Dr. David C. Myles Ph.D. | Chief Discovery and Non-Clinical Development Officer |
| Sasha Austin CPA | Vice President of Finance and Controller |
Latest SEC Filings
| Date | Type | Title |
|---|---|---|
| Jun 13, 2025 | 8-K | Current Report |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 15, 2025 | SCHEDULE 13G/A | Filing |
| May 13, 2025 | SCHEDULE 13D/A | Filing |
| May 13, 2025 | 10-Q | Quarterly Report |
| May 13, 2025 | 8-K | Current Report |
| Apr 28, 2025 | ARS | Filing |
| Apr 28, 2025 | DEFA14A | Additional definitive proxy soliciting materials and Rule 14(a)(12) material |
| Apr 28, 2025 | DEF 14A | Other definitive proxy statements |